PeptidePedia The community reference

Sharps disposal: difference between revisions

Diff·revision 42 → 43·02:55, 30 Jun 2026

Difference between revision 42 and revision 43 of Sharps disposal. 9 lines changed; the page grew by 1,444 bytes.

Revision 42 — 23:30, 28 Jun 2026
TitrationTheo (talk)
split overlong sentence
18,558 bytes ±0
Revision 43 — 02:55, 30 Jun 2026
CiteBot (talk)
bot: sort category members
20,002 bytes +1,444
120Guidance documents differ on whether to describe substitutes at all. The argument against is that describing them normalises non-compliant practice; the argument in favour is that the alternative in practice is not a compliant container but loose sharps in a bag. Public-health guidance addressed to people who inject drugs has generally taken the second position, on harm-reduction grounds, and this is the framing under which the topic is treated at [[Peptide harm reduction]].{{r|who2015sharps}}120Guidance documents differ on whether to describe substitutes at all. The argument against is that describing them normalises non-compliant practice; the argument in favour is that the alternative in practice is not a compliant container but loose sharps in a bag. Public-health guidance addressed to people who inject drugs has generally taken the second position, on harm-reduction grounds, and this is the framing under which the topic is treated at [[Peptide harm reduction]].{{r|who2015sharps}}
121121
+122An unlabelled improvised container also transfers risk to a third party who cannot know what it contains. Labelling is the requirement most easily satisfied outside a clinical setting and the one most often omitted.
+123
+124== Upstream prevention ==
+125Container standards address the sharp after use. A parallel body of regulation addresses whether a conventional sharp is used at all.
+126
+127Safety-engineered devices incorporate a mechanism that shields or retracts the needle after use: sliding sleeves, hinged caps, retracting cannulae and blunting devices. Directive 2010/32/EU requires their use in European hospital and healthcare settings where a risk assessment identifies exposure risk, and the equivalent United States requirement arises from the needlestick-prevention amendments to the occupational bloodborne-pathogens standard, which oblige employers to evaluate and adopt safer devices and to document the evaluation.{{r|eu2010,osha1910}}
+128
+129The World Health Organization's 2015 guideline extends the argument to injections generally, recommending syringes with reuse-prevention features and, separately, syringes with sharps-injury-protection features for injections in healthcare settings. The guideline is explicit that its recommendations are directed at healthcare settings and that the evidence base for effectiveness rests substantially on observational before-and-after studies rather than on randomised comparisons.{{r|who2015sharps}}
+130
122== References ==131== References ==
123{{reflist}}132{{reflist}}